Compound ID | 1868
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis; carbapenems bind to all PBPs, with PBP2 and PBP4 as the highest-affinity targets; carbapenems have a very broad spectrum including non-fermenters and are not hydrolysed by most beta-lactamases with exception of carbapenemases; PBP inhibitor |
| Description: | Semisynthetic, derived from thienamycin, similar to ertapenem; clinical development only for China |
| Institute where first reported: | Sihuan Pharmaceutical |
| Year first mentioned: | 2015 |
| Highest development stage: | Phase 2/ Phase 3 (NCT04505683) |
| Development status: | Active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/58326208 |
| Guide to Pharmacology: | benapenem |
| Citation: | https://journals.asm.org/doi/10.1128/AAC.02188-18 |